S100A8-S100A9 Protein Complex Mediates Psoriasis by Regulating the Expression of Complement Factor C3

Immunity

Volumn 39, Issue 6, 2013, Pages 1171-1181

  Schonthaler, Helia B ^a   Guinea Viniegra, Juan ^a   Wculek, Stefanie K ^a   Ruppen, Isabel ^b   Ximénez Embún, Pilar ^b   Guío Carrión, Ana ^a   Navarro, Raquel ^c   Hogg, Nancy ^d   Ashman, Keith ^b   Wagner, Erwin F ^a  

^a BBVA University Institute for Economic and Social Analysis University of Alcalá   (Spain)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN; CALGRANULIN A; CALGRANULIN B; COMPLEMENT COMPONENT C3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DERMATITIS; EPIDERMIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KERATINOCYTE; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; PSORIASIS; REGULATORY MECHANISM; TISSUE LEVEL;

EID: 84890192032     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2013.11.011     Document Type: Article

References (48)

1. Abtin A., Eckhart L., Gläser R., Gmeiner R., Mildner M., Tschachler E. The antimicrobial heterodimer S100A8/S100A9 (calprotectin) is upregulated by bacterial flagellin in human epidermal keratinocytes. J.Invest. Dermatol. 2010, 130:2423-2430.
2. Acevedo F., Hammar H. Complement C3 proteins in psoriasis. Br. J. Dermatol. 1989, 121:329-335.
3. Arwert E.N., Hoste E., Watt F.M. Epithelial stem cells, wound healing and cancer. Nat. Rev. Cancer 2012, 12:170-180.
4. Baker J.R., Jeffery R., May R.D., Mathies M., Spencer-Dene B., Poulsom R., Hogg N. Distinct roles for S100a8 in early embryo development and in the maternal deciduum. Dev. Dyn. 2011, 240:2194-2203.
5. Barbe L., Lundberg E., Oksvold P., Stenius A., Lewin E., Björling E., Asplund A., Pontén F., Brismar H., Uhlén M., Andersson-Svahn H. Toward a confocal subcellular atlas of the human proteome. Mol. Cell. Proteomics 2008, 7:499-508.
6. Basset-Séguin N., Porneuf M., Dereure O., Mils V., Tesnières A., Yancey K.B., Guilhou J.J. C3d,g deposits in inflammatory skin diseases: use of psoriatic skin as a model of cutaneous inflammation. J.Invest. Dermatol. 1993, 101:827-831.
7. Bayry J., Lacroix-Desmazes S., Kazatchkine M.D., Kaveri S.V. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. Nat. Clin. Pract. Rheumatol. 2007, 3:262-272.
8. Bexborn F., Andersson P.O., Chen H., Nilsson B., Ekdahl K.N. The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb). Mol. Immunol. 2008, 45:2370-2379.
9. Dalakas M.C. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 2004, 291:2367-2375.
10. Di Meglio P., Perera G.K., Nestle F.O. The multitasking organ: recent insights into skin immune function. Immunity 2011, 35:857-869.
11. Gebhardt C., Németh J., Angel P., Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem. Pharmacol. 2006, 72:1622-1631.
12. Gebhardt C., Riehl A., Durchdewald M., Németh J., Fürstenberger G., Müller-Decker K., Enk A., Arnold B., Bierhaus A., Nawroth P.P., et al. RAGE signaling sustains inflammation and promotes tumor development. J.Exp. Med. 2008, 205:275-285.
13. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
14. Guinea-Viniegra J., Zenz R., Scheuch H., Hnisz D., Holcmann M., Bakiri L., Schonthaler H.B., Sibilia M., Wagner E.F. TNFalpha shedding and epidermal inflammation are controlled by Jun proteins. Genes Dev. 2009, 23:2663-2674.
15. Gurmin V., Mediwake R., Fernando M., Whittaker S., Rustin M.H., Beynon H.L. Psoriasis: response to high-dose intravenous immunoglobulin in three patients. Br. J. Dermatol. 2002, 147:554-557.
16. Guttman-Yassky E., Lowes M.A., Fuentes-Duculan J., Zaba L.C., Cardinale I., Nograles K.E., Khatcherian A., Novitskaya I., Carucci J.A., Bergman R., Krueger J.G. Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J.Immunol. 2008, 181:7420-7427.
17. Hobbs J.A., May R., Tanousis K., McNeill E., Mathies M., Gebhardt C., Henderson R., Robinson M.J., Hogg N. Myeloid cell function in MRP-14 (S100A9) null mice. Mol. Cell. Biol. 2003, 23:2564-2576.
18. Javkhlan P., Hiroshima Y., Azlina A., Hasegawa T., Yao C., Akamatsu T., Kido J., Nagata T., Hosoi K. Lipopolysaccharide-mediated induction of calprotectin in the submandibular and parotid glands of mice. Inflammation 2011, 34:668-680.
19. Johansen C., Kragballe K., Rasmussen M., Dam T.N., Iversen L. Activator protein 1 DNA binding activity is decreased in lesional psoriatic skin compared with nonlesional psoriatic skin. Br. J. Dermatol. 2004, 151:600-607.
20. Kerkhoff C., Voss A., Scholzen T.E., Averill M.M., Zänker K.S., Bornfeldt K.E. Novel insights into the role of S100A8/A9 in skin biology. Exp. Dermatol. 2012, 21:822-826.
21. Leon F., Contractor N., Fuss I., Marth T., Lahey E., Iwaki S., la Sala A., Hoffmann V., Strober W., Kelsall B.L. Antibodies to complement receptor 3 treat established inflammation in murine models of colitis and a novel model of psoriasiform dermatitis. J.Immunol. 2006, 177:6974-6982.
22. Leukert N., Vogl T., Strupat K., Reichelt R., Sorg C., Roth J. Calcium-dependent tetramer formation of S100A8 and S100A9 is essential for biological activity. J.Mol. Biol. 2006, 359:961-972.
23. Lowes M.A., Bowcock A.M., Krueger J.G. Pathogenesis and therapy of psoriasis. Nature 2007, 445:866-873.
24. Lutz H.U., Stammler P., Bianchi V., Trüeb R.M., Hunziker T., Burger R., Jelezarova E., Späth P.J. Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood 2004, 103:465-472.
25. Manitz M.P., Horst B., Seeliger S., Strey A., Skryabin B.V., Gunzer M., Frings W., Schönlau F., Roth J., Sorg C., Nacken W. Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants invitro. Mol. Cell. Biol. 2003, 23:1034-1043.
26. Markiewski M.M., Lambris J.D. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am. J. Pathol. 2007, 171:715-727.
27. Monsinjon T., Gasque P., Chan P., Ischenko A., Brady J.J., Fontaine M.C. Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J. 2003, 17:1003-1014.
28. Nacken W., Roth J., Sorg C., Kerkhoff C. S100A9/S100A8: Myeloid representatives of the S100 protein family as prominent players in innate immunity. Microsc. Res. Tech. 2003, 60:569-580.
29. Nakatsuji T., Gallo R.L. Antimicrobial Peptides: Old Molecules with New Ideas. J.Invest. Dermatol. 2011, 132:887-895.
30. Németh J., Stein I., Haag D., Riehl A., Longerich T., Horwitz E., Breuhahn K., Gebhardt C., Schirmacher P., Hahn M., et al. S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis. Hepatology 2009, 50:1251-1262.
31. Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N.Engl. J. Med. 2009, 361:496-509.
32. Palamara F., Meindl S., Holcmann M., Lührs P., Stingl G., Sibilia M. Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J.Immunol. 2004, 173:3051-3061.
33. Ricklin D., Lambris J.D. Compstatin: a complement inhibitor on its way to clinical application. Adv. Exp. Med. Biol. 2008, 632:273-292.
34. Robinson M.J., Hogg N. A comparison of human S100A12 with MRP-14 (S100A9). Biochem. Biophys. Res. Commun. 2000, 275:865-870.
35. Schonthaler H.B., Huggenberger R., Wculek S.K., Detmar M., Wagner E.F. Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. Proc. Natl. Acad. Sci. USA 2009, 106:21264-21269.
36. Suzuki H., Wang B., Shivji G.M., Toto P., Amerio P., Tomai M.A., Miller R.L., Sauder D.N. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J.Invest. Dermatol. 2000, 114:135-141.
37. Swamy M., Jamora C., Havran W., Hayday A. Epithelial decision makers: in search of the 'epimmunome'. Nat. Immunol. 2010, 11:656-665.
38. Tohyama M., Hanakawa Y., Shirakata Y., Dai X., Yang L., Hirakawa S., Tokumaru S., Okazaki H., Sayama K., Hashimoto K. IL-17 and IL-22 mediate IL-20 subfamily cytokine production in cultured keratinocytes via increased IL-22 receptor expression. Eur. J. Immunol. 2009, 39:2779-2788.
39. van der Fits L., Mourits S., Voerman J.S., Kant M., Boon L., Laman J.D., Cornelissen F., Mus A.M., Florencia E., Prens E.P., Lubberts E. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J.Immunol. 2009, 182:5836-5845.
40. van Lent P.L., Hofkens W., Blom A.B., Grevers L., Sloetjes A., Takahashi N., van Tits L.J., Vogl T., Roth J., de Winther M.P., van den Berg W.B. Scavenger receptor class A type I/II determines matrix metalloproteinase-mediated cartilage destruction and chondrocyte death in antigen-induced arthritis. Arthritis Rheum. 2009, 60:2954-2965.
41. Venkatesha R.T., Berla Thangam E., Zaidi A.K., Ali H. Distinct regulation of C3a-induced MCP-1/CCL2 and RANTES/CCL5 production in human mast cells by extracellular signal regulated kinase and PI3 kinase. Mol. Immunol. 2005, 42:581-587.
42. Vogl T., Leukert N., Barczyk K., Strupat K., Roth J. Biophysical characterization of S100A8 and S100A9 in the absence and presence of bivalent cations. Biochim. Biophys. Acta 2006, 1763:1298-1306.
43. Wagner E.F., Schonthaler H.B., Guinea-Viniegra J., Tschachler E. Psoriasis: what we have learned from mouse models. Nat Rev Rheumatol 2010, 6:704-714.
44. Wolf R., Mascia F., Dharamsi A., Howard O.M., Cataisson C., Bliskovski V., Winston J., Feigenbaum L., Lichti U., Ruzicka T., et al. Gene from a psoriasis susceptibility locus primes the skin for inflammation. Sci. Transl. Med. 2010, 2:61ra90.
45. Wolf R., Ruzicka T., Yuspa S.H. Novel S100A7 (psoriasin)/S100A15 (koebnerisin) subfamily: highly homologous but distinct in regulation and function. Amino Acids 2011, 41:789-796.
46. Wyatt R.J., Wang C., Hudson E.C., Jones R.M., Noah P.W., Rosenberg E.W. Complement phenotypes in patients with psoriasis. Hum. Hered. 1989, 39:327-332.
47. Zenz R., Eferl R., Kenner L., Florin L., Hummerich L., Mehic D., Scheuch H., Angel P., Tschachler E., Wagner E.F. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005, 437:369-375.
48. Zenz R., Eferl R., Scheinecker C., Redlich K., Smolen J., Schonthaler H.B., Kenner L., Tschachler E., Wagner E.F. Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease. Arthritis Res. Ther. 2008, 10:201.